Products - Metastases | Topic

Showing 27 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer ID6425
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases ID6512
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Metastases Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 27 products

Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523

Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810

Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822

Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer ID6425

Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460

Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044

Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040

Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases ID6512

Metastases Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 27 products

Status
1 selected